IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, is reporting on its preclinical research that demonstrates the therapeutic potential of IGC-1C, a novel small-molecule modulator. According to the announcement, IGC-1C targets tau protein and GLP-1 receptors, offering a multipathway approach to neurodegenerative and metabolic disease treatment. A cyclic dipeptide-based, small-molecule modulator, IGC-1C is a pioneering approach to addressing tau-related pathology.
“Our discovery of IGC-1C’s potential dual action, targeting both tau and GLP-1 receptors, marks a significant advancement in our Alzheimer’s disease research and treatment,” said IGC Pharma CEO Ram Mukunda in the press release. “This innovative approach aligns with our broader strategy to develop and leverage several assets in the metabolic disease space, aiming to improve treatment outcomes for Alzheimer’s, metabolic disorders and obesity. By addressing the emerging focus on tau tangles and incorporating GLP-1 receptor modulation, IGC-1C positions itself at the forefront of developing transformative therapies, providing a comprehensive strategy for slowing progression and improving patient outcomes. We are committed to advancing our molecules through future clinical trials, fully realizing its potential to deliver transformative therapies and drive substantial value for our shareholders.”
To view the full press release, visit https://ibn.fm/piXrR
About IGC Pharma
IGC Pharma is an artificial intelligence (“AI”)-powered, clinical-stage biotechnology company focused on developing innovative treatments for Alzheimer’s disease and transforming patient care with fast-acting, safe and effective solutions. The company’s portfolio includes the TGR family, including TGR-63, which targets amyloid plaques, a hallmark of Alzheimer’s. The IGC-C and IGC-M platforms are advancing in preclinical stages, focusing on metabolic disorders, tau proteins, early plaque formation and multiple disease hallmarks. IGC Pharma’s lead therapeutic candidate, IGC-AD1, is a cannabinoid-based treatment currently in a phase 2 trial for agitation in dementia associated with Alzheimer’s. Interim data for IGC-AD1 demonstrated that it has the potential to transform patient care by offering faster-acting and more effective relief compared to traditional medications. Additionally, the company’s AI models are designed to predict potential biomarkers for the early detection of Alzheimer’s, optimize clinical trials and predict receptor affinity, among others. With 28 patent filings and a commitment to innovation, IGC Pharma is dedicated to advancing pharmaceutical treatments and improving the lives of those affected by Alzheimer’s and related conditions. For more information, visit the company’s website at www.IGCInc.us.
NOTE TO INVESTORS: The latest news and updates relating to IGC are available in the company’s newsroom at https://ibn.fm/IGC
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]
InvestorWire is powered by IBN